Can you tell me more about RCBM’s Spravato program?
Major Depressive Disorder (MDD) is one of the most common mental health disorders in the United States. Treatments such as psychotherapy, medication management, and lifestyle changes may help relieve symptoms. However, other individuals may have Treatment Depression (TRD) and continue to experience symptoms such as persistent feelings of sadness, sleep disturbances, low energy, and thoughts of death or suicide despite trying multiple treatments.
Taken along with an oral antidepressant, SPRAVATO® is the first nasal spray medication specifically for adults with treatment-resistant depression.
Taken along with an oral antidepressant, SPRAVATO® is the first nasal spray medication that treats depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions.
The U.S. Food & Drug Administration approved SPRAVATO® on March 5, 2019, and is only available to patients at certified treatment centers in the United States, such as Rochester Center for Behavioral Medicine (RCBM).
SPRAVATO® is a prescription medication, used along with an antidepressant taken by mouth, for TRD in adults.
This treatment is approved for adults ages 18 and older.
